Clinical Trial

Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Study acronym: BelaRd
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-03-18.
Status change: Recruiting → Active, Not Recruiting 2023-10-23
Trial Details
NCT Number NCT04808037
Lead Sponsor Hellenic Society of Hematology
Collaborators: GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 66 participants
Start Date 2021-02-22
Primary Completion 2028-09-08 (estimated)
Study Completion 2028-11-08 (estimated)
Updated on ClinicalTrials.gov 2023-10-24